Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer / M.L. Gillison, G. Blumenschein, J. Fayette, J. Guigay, A.D. Colevas, L. Licitra, K.J. Harrington, S. Kasper, E.E. Vokes, C. Even, F. Worden, N.F. Saba, L.C. Iglesias Docampo, R. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Monga, M. Lynch, L. Li, R.L. Ferris. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 23:9(2018 Sep), pp. 1079-1082. [10.1634/theoncologist.2017-0674]

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

L. Licitra;
2018

Abstract

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
Settore MED/06 - Oncologia Medica
set-2018
4-giu-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
CheckMate 141.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 546.26 kB
Formato Adobe PDF
546.26 kB Adobe PDF [it] Default value:   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/580073
Citazioni
  • ???jsp.display-item.citation.pmc??? 54
  • Scopus 92
  • ???jsp.display-item.citation.isi??? 87
  • OpenAlex ND
social impact